Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

27 May 2016
Change (% chg)

-0.70p (-0.42%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for VEC.L


Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to... (more)


Beta: 0.39
Market Cap(Mil.): £679.57
Shares Outstanding(Mil.): 410.62
Dividend: --
Yield (%): --


  VEC.L Industry Sector
P/E (TTM): 144.79 35.22 36.14
EPS (TTM): 0.01 -- --
ROI: 1.98 13.74 13.10
ROE: 2.18 14.88 14.37

BRIEF-Vectura FY core earnings rise 43 pct

* EBITDA(1) up 43% to £23.2m (2014/15: £16.2m) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

26 May 2016

BRIEF-Vectura & Propeller Health announce collaboration

* Vectura and propeller health announce collaboration to develop digitally-connected inhalers to address chronic respiratory diseases Source text for Eikon: Further company coverage:

24 May 2016

BRIEF-Vectura Group says CMA not to investigate Vectura-Skyepharma merger

* CMA has confirmed that proposed recommended all share merger of Vectura and Skyepharma does not qualify for investigation

16 May 2016

BRIEF-UK's CMA says no relevant merger situation in Vectura-Skyepharma deal

* UK's CMA says decided that a relevant merger situation has not been created in anticipated acquisition by Vectura Group Plc of Skyepharma Plc Source text for Eikon:

16 May 2016

Drugmaker Vectura Group to buy SkyePharma

March 16 Drugmaker Vectura Group said on Wednesday it would buy SkyePharma Plc in an all-stock deal that would give it SkyePharma's drug delivery platform.

16 Mar 2016

BRIEF-HBM Healthcare Investments says Skyepharma to merge with Vectura group

* Under the terms of the proposed merger, Skyepharma shareholders will be entitled to receive 2.7977 new Vectura shares for every Skyepharma share

16 Mar 2016

BRIEF-Vectura Group to buy Skyepharma for 441.3 million stg

* Vectura Group and Skyepharma Plc have reached agreement on terms of a recommended merger between Vectura and Skyepharma

16 Mar 2016

BRIEF-Vectura says clinical study report for asthma therapy VR315 now final

* Next planned milestone and announcement scheduled for this programme is $10 million due to be paid upon acceptance for filing of ANDA by FDA

10 Feb 2016

BRIEF-Vectura completes clinical trial for asthama therapy

* Is eligible to receive a further $23 mln upon achievement of future pre-determined development milestones on VR315 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

08 Jan 2016

BRIEF-Vectura says to receive milestone payment of $3.75 mln

* Commencement of first phase III trial of inhaled triple therapy QVM149 for asthma and milestone payment

09 Dec 2015

Earnings vs. Estimates